Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Anti-Mac-1-saporin** is an experimental immunotoxin consisting of an antibody directed against Mac-1 (also known as CD11b, a beta-2 integrin highly expressed on microglia and macrophages) chemically conjugated to the ribosome-inactivating protein **saporin**. The antibody component provides high specificity for cells expressing Mac-1/CD11b, and, upon antibody-mediated binding and internalization, the saporin toxin inactivates ribosomes, thereby causing selective cell death. This approach allows for targeted ablation of microglia and macrophages in vivo or in vitro. Anti-Mac-1-saporin is primarily used as a research tool to investigate the roles of these immune cells in disease models (e.g., inflammation, neurodegeneration, colitis) and in mechanisms of tissue repair and immune homeostasis. It is not a marketed pharmaceutical product but is commercially available for research from specialized reagent suppliers[2][6][1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-Mac-1-saporin.